Regenerage, IIMET, and Bioquark, Inc. are undertaking a 12-week clinical trial, of a novel topical formulation, to study biologic reversal of aging in photodamaged skin.
CHICAGO, PHILADELPHIA, AN ZAPOPAN, MEXICO (PRWEB) JULY 18, 2019
Regenerage International Inc., a clinical company focused on therapeutic and consumer applications of regenerative healthcare; IIMET, a Mexico based contract research organization (CRO); and Bioquark, Inc., a life sciences company focused on the development of novel combinatorial bioproducts for regeneration and disease reversion, have announced a 12-week, placebo controlled, human clinical trial to study the biologic age-reversal properties of a twice daily application, of a novel topical formulation (RGR-003) in 10 subjects with photodamaged skin.
“We are very excited about this upcoming study of RGR-003,” said Dr. Joel Osorio, Founder of Regenerage. “In 2019, the ability to study multiple levels of skin biodynamics in human subjects, at the tissue structure, cellular, biomolecular, and genetic levels, opens up new possibilities to understand and intervene in various dermatological conditions, including biologic aging.”
Skin represents the largest organ in the human body, containing miles of vasculature and nerves, billions of pores and corpuscles, complex 3D architecture, and undertakes multifaceted biochemical, biomechanical, and bioelectric signaling with all organ systems encased within.
“Biologic aging” refers to the integrated negative changes that occur across these systems and represent the core drivers of downstream disease and degeneration.
Skin disorders, including cancers, autoimmune diseases, inflammatory conditions, and allergies, represent hundreds of billions of dollars annually, globally, in direct and indirect costs, and all have biologic aging processes as core drivers to their progression. Recent studies in the peer reviewed scientific literature are even beginning to connect skin damage, genetic changes and related “inflamm-aging” signaling factors to a wide variety of chronic diseases throughout the body’s organ systems, including Alzheimer’s, Heart Disease and Diabetes.
“We look forward to working closely with Regenerage and Bioquark on this exciting initiative,” said Dr Geannyne Villegas Rivera, IIMET Principal Investigator. “The ability to combine our novel testing resources, with their novel biologic approaches, offers the opportunity to look deeper at disease transitions and effect beneficial changes in human pathology, including aging, as opposed to just effecting symptoms of conditions.”
The ability to turn back biologic age, in a controlled manner, across various tissues, organs, and body segments, is a ubiquitous process found in many species in the animal kingdom, including many fish, amphibians, and invertebrates. Those organisms capable of this age reversal, possess the inherent ability to re-establish both the embryogenic potential of their genomes and the step-wise morphodynamic remodeling of their tissues.
“This study is another step forward for us in validating our strategy of creating combinatorial bioproducts, such as RGR-003, that can both reprogram and remodel human tissues in-vivo, for comprehensive regeneration and rejuvenation purposes”, said Ira Pastor, CEO of Bioquark Inc.
About Regenerage International Inc.
Regenerage International is a novel clinical company focused on translational therapeutic applications of regenerative medicines, as well as developing consumer wellness and therapeutic skin care products – (http://regeneragebeauty.com/)
IIMET (Centro de Investigacion e Innovacion en Medicina Traslacional) is a Mexico based CRO focused on clinical research with a translational approach. It specializes in protocols with innovative products that contribute to improving the quality of life of their patients. It is made up of a multidisciplinary team of doctors and health personnel with extensive experience in clinical research protocols. Instituto Jalisciense De Investigacion Clinica S.A. de C.V. serves as the IIMET independent review board – (http://www.ijicsa.com/)
About Bioquark, Inc.
Bioquark Inc. is a novel life sciences company focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration – (http://www.bioquark.com)
“This study is another step forward for us in validating our strategy of creating combinatorial bioproducts that can both reprogram and remodel human tissues for comprehensive regeneration and rejuvenation purposes”, said Ira Pastor, CEO of Bioquark Inc.